Drugs / Bioactive glass
Bioactive glass
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT06764732 | Nov 2022 → Nov 2023 | — | Al-Azhar University | Completed | No outcome recorded |
| — | NCT02796911 | Sep 2015 → Jul 2016 | malposition of teeth with or without hypodontia/oligodontia | King Abdulaziz University | Completed | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT02982681 Comparator | Apr 2015 → Aug 2016 | bone resorption disease, chronic periodontitis | Dr. D. Y. Patil Dental College & Hospital | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05484492 Comparator | Oct 2022 → Oct 2025 | bone resorption disease | University of Louisville | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07063433 Comparator | Feb → May 2025 | dentin sensitivity | British University In Egypt | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bioactive glass | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02796911 ↗ |
| Known as | Bio-Glass | “group III will be treated with CAOT combined with bioactive glass (Bio-Glass, Excellence Pharm Inc., Egypt).” NCT02796911 ↗ |
| Known as | NovaBone | “The positive control group of fifteen patients will receive an intrasocket synthetic resorbable calcium phosphosilicate putty alloplast graft (NovaBone, Osteogenics) covered...” NCT05484492 ↗ |
| Modality | Other / unclassified | “bioactive glass” NCT02796911 ↗ |
| Route | Other | “intrasocket” NCT05484492 ↗ |